Alkermes, Inc.

NASDAQ: ALKS
$16.74
+$0.21 (+1.3%)
Closing price September 25, 2020
Friday's top analyst upgrades, downgrades and initiations included Alkermes, Aurora Cannabis, BlackRock, Duke Energy, Nvidia, Ralph Lauren, SunPower, Veeva Systems and Yelp.
Biogen and Alkermes have announced that the FDA approved Vumerity for the treatment of relapsing forms of multiple sclerosis.
Alkermes shares made a handy gain on Monday after the firm announced that it would be expanding its New Drug Application for ALKS 3831 to encompass the treatment of bipolar I disorder in addition to...
The top analyst upgrades, downgrades and initiations on Monday included Agilent Technologies, Amazon.com, American Water Works, Crocs, Deere, General Electric, Gilead Sciences, Slack and Teva...
The top analyst upgrades, downgrades and initiations seen on Friday included Alkermes, Apple, Canada Goose, FireEye, J.Jill, Kraft Heinz, Uber Technologies and Vonage.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alkermes, Alphabet, Apple, ConocoPhillips, FireEye, Lyft, McDonald's, Royal Bank of Scotland, Seagate Technology and...
The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Baker Hughes, Biogen, FedEx, Intel, Micron Technology, Roku and Shake Shack.
Alkermes shares dropped early on Friday after the company anncounced the results from its most recent meeting with the U.S. Food and Drug Administration.
The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
The top analyst upgrades, downgrades and other research calls from Wednesday include Alkermes, Cigna, International Paper, Medtronic, Tesla and Western Digital.
The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
Shares of Alkermes saw a handy gain to start out the week after the FDA made a critical decision about its treatment for major depressive disorder.
Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter from the FDA.
The top analyst upgrades, downgrades and other research calls from Thursday include Alkermes, ArQule, Bluebird Bio, Cognizant Technology Solutions, Ecolab, KLA-Tencor, Pandora Media, Verisk Analytics...
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.